ther studies in patients with CRF are necessary to define the Efficacy of 19-Nor-1,25-(OH) 2 D 2 in the prevention and treatclinical applicability of 19-Nor on bone histology in humans. ment of hyperparathyroid bone disease in experimental uremia.
In patients with chronic renal failure (CRF), parathyParathyroid gland enlargement and elevated levels of PTH are roid hyperplasia, and enhanced synthesis and secretion major contributors to increase bone resorption, a feature of renal osteodystrophy.
of parathyroid hormone (PTH) characterize secondary
Methods. These studies assessed the efficacy of the 1, 25(OH) 2 D 3 hyperparathyroidism (SH) [1] [2] [3] [4] . The enlargement of the analog, 19-Nor-1,25(OH) 2 D 2 , in the prevention (protoparathyroid glands and high circulating levels of PTH [5] col I) and treatment (protocol II) of SH and renal osteodystrophy are major contributors to increased bone resorption, a in uremic rats. In protocol I, normal and uremic rats were fed a feature of renal osteodystrophy. Uremia, low calcium high phosphorus diet for 2 months; uremic rats were administered intraperitoneal injections of either vehicle or intake, high dietary phosphorus, and vitamin D deficiency three times a week). In protocol II, normal and uremic rats are the main regulators of SH [6] . Although the mechawere fed a high phosphorus diet for 4 months; 2 months after nisms by which these factors control PTH biosynthesis the onset of uremia, rats were administered either intraperitoand secretion are well known, optimal treatments are neal vehicle or 19-Nor (200 ng three times a week). Serum PTH and bone histology were used to assess the degree of SH. still being developed.
Results. 19-Nor was effective in preventing (protocol I) and 1, 25(OH) 2 D 3 (1,25D) has been used in the treatment suppressing (protocol II) the significant SH induced by uremia of SH because of its efficacy in suppressing PTH secreand further enhanced by a high phosphorus diet. In protocol tion and synthesis [7] . However, both hypercalcemia and I, bone histology in uremic controls showed a threefold increase hyperphosphatemia, a result of increased intestinal calin the cancellous bone mass compared to normal rats. This expansion in unmineralized bone was accompanied by 5-, 1.5-, cium and phosphorus absorption and bone-mineral reand 7-fold increases in eroded surface, mineralization lag time sorption, may develop in some patients, thus, this may (MLT) , and bone formation rate (BFR/BS), respectively. Morepreclude 1,25D use in these uremic patients. In addition, over, cortical bone porosity in untreated uremic rats increased 1,25D-induced enhancement of serum calcium levels pro-267-fold compared to normal animals. 19-Nor ameliorated these motes an elevated calcium-phosphate product increasing changes in cancellous and cortical bone. In protocol II, the reported indices worsened even further. In contrast, 2 months of the risk of vascular calcification especially in patients 19 -Nor treatment improved bone histology by reducing cortical receiving calcium salts as phosphate binders [8, 9] (1,25D) , suppresses PTH in uremic rats phometric changes induced by uremia and high phosphorus diet. In addition, 19-Nor suppresses serum PTH and improves with SH at doses which do not increase either serum bone histology in uremic rats with established severe SH. Furcalcium or phosphorus [10, 11] . The mechanisms responsible for the decreased calcemic and phosphatemic activiapproximately 10 times less active than 1,25D in promoting calcium and phosphorus resorption from bone [12] .
 2003 by the International Society of Nephrology However, both promote bone differentiation of the osteo-19-Nor (N ϭ 8) as in protocol I, except that the injections were begun 2 months after the induction of renal failure blast phenotype, which is required for normal bone formation. Furthermore, 19-Nor is currently used in hemodialand continued for an additional 2 months. For both protocols all rats received subcutaneous injections of a tetraysis patients as an alternative to 1,25D therapy [13] .
1,25D not only potently stimulates bone resorption cycline derivative, demeclocycline (#D-614) (Sigma Chemical Co., St. Louis, MO, USA), 20 mg/kg, 12 days before but also promotes bone formation. The effects of 1,25D on osteoblasts and their precursors, which are multiple sacrifice. In addition, both 2-and 4-month uremic and normal animals were injected subcutaneously with calcein and complex, include (1) decreasing the rate of cell proliferation, while enhancing the process of mineralization;
(#C-0875) (Sigma Chemical Co.), 10 mg/kg, 2 days before sacrifice (10 days after the demeclocycline administration). (2) increasing both gene and protein expression of a number of matrix proteins, including type 1 collagen, osteoAt the end of each study, normal and uremic rats were anesthetized and sacrificed by exsanguination. Arterial calcin, and osteopontin; and (3) stimulating production of the ectoenzyme alkaline phosphatase and the growth blood was drawn by aortic puncture for analytic determinations. After sacrifice, tibiae were surgically removed, factors, transforming growth factor-␤ (TGF-␤) and insulin-like growth factor-1 (IGF-1), as well as the family of stripped of all muscle, and saved for histomorphometric analysis of cancelleous and cortical bone. binding proteins that modulates the activity of the latter molecule [14] . Studies in patients with CRF demonAll experimental protocols were approved by the Animal Studies Committee at Washington University School strated that, in some patients, the administration of calcitriol induced adynamic bone disease [15] . Concern of Medicine. that prolonged 19-Nor therapy might have negative side Analytic determinations effects on the bone metabolism of hemodialysis patients led us to examine two markers of bone formation, alkaPlasma phosphorus and creatinine were determined using an autoanalyzer (COBAS-MIRA Plus, Branchline phosphatase and osteocalcin in MG-63 cells, an osteoblastic-like cell line [16] . These in vitro studies sugburg, NJ, USA). Ionized calcium was measured by an ionized calcium-specific electrode (Model ICA-1; Radigested that 19-Nor is as active as 1,25D in promoting bone formation.
ometer, Copenhagen, Denmark). Intact PTH levels were measured by an immunoradiometric assay specific for In the present studies, we examined the in vivo effects of 19-Nor administration on bone. In our experimental rat intact PTH (Immutopics, San Clemente, CA, USA). model of CFR, 19-Nor therapy not only prevents SH Tetracycline derivative preparation and ameliorates the histomorphometric alterations induced by uremia and high dietary phosphorus, but also Thirty minutes prior to injection, demeclocycline powder was mixed with bacteriostatic water, stirred, and suppresses serum PTH and improves bone histology in uremic rats with established severe SH.
adjusted for a pH between 7.2 and 7.4. Calcein powder was slowly added to a sodium bicarbonate saline solution and stirred until dissolved. This solution was filtered METHODS through a 0.2 millipore filter, mixed, and used for the Experimental protocols injections. Normal and uremic (5/6 nephrectomized) female Bone histomorphometry Sprague-Dawley rats, 8 to 10 weeks old and weighing 225 to 250 g, were studied. The 5/6 nephrectomy involved
Immediately after removal of all muscles, tibiae were fixed in 70% alcohol. The proximal portion and the midthe ligation of several branches of the left renal artery and excision of the right kidney. All animals were fed a dle third of the right tibiae were stained with Villanueva stain, dehydrated in graded concentrations of ethanol, high phosphorus diet containing 0.9% phosphorus and 0.6% calcium, purchased from Dyets, Inc. (Bethlehem, defatted in acetone, and embedded in methyl methacrylate (Fisher Scientific, Fairlaw, NJ, USA). Longitudinal PA, USA).
Protocol I. During the studies, normal rats (control sections of the proximal portion of the tibiae and cross sections at the tibiofibular junctions of the tibial shafts group) (N ϭ 9) received 100 L of propylene glycol as vehicle, three times a week for 2 months. Immediately were cut to a thickness of 230 m using a low speed metallurgic saw and then ground to thicknesses of 20 m after the onset of renal failure, uremic rats received intraperitoneal injections of either 100 L of propylene glycol (proximal portion of the tibiae) and 30 m (tibiofibular junctions of the tibial shafts) for histomorphometric meaas vehicle (N ϭ 8) or (N ϭ 9) three times a week for 2 months.
surement. Histomorphometry was done using a semiautomatic image analysis system (OsteoMeasure, OsteoProtocol II. Normal rats (N ϭ 8) received 100 L of propylene glycol as vehicle, three times a week for 4
Metrics, Inc., Decatur, GA, USA) linked to a microscope equipped with transmitted and fluorescence light. All months, uremic rats received either vehicle (N ϭ 8) or [17, 18] . 
, depicts the abbreviations for the bone histomorphomeosteoid perimeter (OPm) (%), periosteal-bone formatric indices used in these analyses. tion rate (Ps-BFR) (m/day/100) ( Tables 1 and 3) . Figure 1 depicts the experimental design for the protoFor the biochemical analyses, analysis of variance cols for prevention and treatment studies. In protocol I, (ANOVA) was employed to assess statistical differences after the onset of renal failure, the rats were divided into between all experimental groups tested. Multiple comtwo groups with similar serum creatinine levels. Uremic parisons using the stringent Bonferroni test measured rats were injected intraperitoneally with vehicle or 19-the statistical significance of the differences between evNor, 3 times a week for 2 months. In protocol II, after ery possible two-group comparisons.
Study design Statistics
2 months of renal failure, uremic rats were divided into For bone histomorphometry, statistical analyses were two groups with similar serum creatinine levels. One performed using SPSS for Windows (version 10.0, SPSS, group received 19-Nor and the other vehicle three times Inc., Chicago, IL, USA). The Bonferroni post-hoc test a week for an additional 2-month period.
Normal rats was selected to analyze differences between groups. P Ͻ (control group) received 100 L of propylene glycol as vehicle three times a week for 2 or 4 months in both 0.05 was considered significant.
protocols.
RESULTS

Effects of 19-Nor on serum chemistry and PTH secretion
The efficacy of 19-Nor in preventing (protocol I) and treating (protocol II) high phosphorus-induced second- Table 2 shows the effects of 19-Nor treatment on serum creatinine, ionized calcium, phosphorus, and PTH ary hyperparathyroidism and bone damage in rats was mal rats very few double labels were observed at either the periosteal or endocortical surfaces. In uremic unfailure. Serum creatinine increased in both 2-and 4-month uremic animals fed high dietary phosphorus compared treated animals, much more bone, osteoid, double labels, wide interlabeled width, diffuse labels, and bone erosion to normal controls. The elevation in serum creatinine levels was lower after 2 and 4 months in uremic rats were seen. In contrast, in 19-Nor-treated rats, more bone of lamellar structure was noted compared to the normal treated with 19-Nor compared to untreated uremic animals. In addition, as indicated in Table 2 , serum phosphocontrols. Moreover, we observed less osteoid, double labeling, intracortical porosity and bone erosion in urerus levels in uremic rats were reduced by 19-Nor administration. As expected, treatment with the vitamin D analog mic rats receiving 19-Nor. did not significantly increase ionized calcium compared Effects of chronic renal failure and 19-Nor on to normal rats fed the same high phosphorus diet.
cancelleous and cortical bone (protocol II Untreated uremic controls in both protocols I and II at 4 months) had higher serum PTH levels than normal controls. In contrast, 19-Nor not only prevented the increase in se- Table 3 shows the static and dynamic histomorphomerum PTH induced by high dietary phosphorus after 2 tric changes observed in the 4-month study. After 4 months of uremia, but also reduced the very high PTH months of CRF, the amount of woven bone was further levels seen in the 4-month study.
increased (↑43%), compared to the 2-month study. Elevated bone turnover (BFR/BV) and prolonged MLT Effects of CRF and 19-Nor on cancelleous and were also seen. Moreover, the total cross-sectional area cortical bone (protocol I at 2 months) of tibiofibular junctions of the tibial shafts increased by 12%, the MaAr decreased by 22%, and the CtWi inFor the 2-month study, Table 3 shows the static and dynamic histomorphometric changes in the PTM and creased by 17%. PoAr was also increased compared to 2-month uremic (169%) and age-matched normal rats the cross sections at the tibiofibular junctions of the tibial shafts. After 2 months of renal failure, total bone mass (700-fold). Importantly, compared to the untreated uremic group, rats receiving 2 months of 19-Nor treatment increased due mainly to increases in woven bone. MLT increased by 48%, while eroded surface and bone formainitiated 2 months after the onset of uremia had lower ES/BS, MLT, and BFR/BV, 79%, 53%, and 88%, respection rate increased by five-to sixfold. In the tibiofibular junctions of the tibial shafts, intracortical porosity area tively. In the tibiofibular junctions of the tibial shafts, porosity area, periosteal bone formation and endocortialso markedly increased from 0.001 Ϯ 0.000 to 0.267 Ϯ 0.01. In addition, both periosteal and endocortical bone cal bone formation decreased 96%, 33%, and 85% respectively, in 19-Nor treated rats versus untreated uremic formation increased by at least 30-fold. Compared to the uremic group, treatment with 19-Nor lowered WBV/TV controls. The effects of 4 months of CRF and 19-Nor treatment to that of normal controls. MLT, ES/BS and BFR/BS were lowered by 45%, 74%, and 37%, respectively. In on both cancellous and cortical bone are showed in Figure 3 A and B, respectively. In uremic untreated rats, uremic rats receiving 19-Nor, PoAr, BFR of the periosteal and BFR of endocortical surfaces were lowered by more cancellous bone, double labels, osteoid, and erosion were seen. The structure of the cortex was distorted 96%, 46%, and 57%, respectively.
The effects of 2 months of CRF and preventive 19-and greater intracortical porosity was present. In contrast, 19-Nor-treated animals had less osteoid, double Nor administration on both cancellous and cortical bone are illustrated in Figure 2 A and B, respectively. In norlabeling, intracortical porosity, and bone erosion. For abbreviations, see Table 1 . Normal (N) and uremic (U) rats underwent one of the following experimental protocols for either 2 or 4 months: normal control ϩ high phosphorus diet ϩ vehicle (N Ϫ HP ϩ V), uremic control ϩ high phosphorus diet ϩ vehicle (U Ϫ HP ϩ V), uremic ϩ HP diet ϩ 200 ng three times a week 
DISCUSSION
hyperphosphatemia in uremic rats [10] . Our results confirm that 19-Nor controls SH by reducing serum PTH These studies assessed the effects of the 1,25D analog, levels, with little effect on serum calcium and phosphorus 19-Nor, in the prevention and treatment of high phoslevels in uremic rats [16] . Moreover, recent studies in phorus-induced secondary hyperparathyroidism and bone humans have reported a 60% reduction in PTH levels damage in a model of experimental uremia.
in hemodialysis patients treated with 19-Nor compared We first studied [protocol I (2 months)] the effect of to those receiving placebo [13] . 19-Nor on the prevention of SH and bone pathology.
It is well known that vitamin D deficiency, an imporSecond, we studied [protocol II (4 months)] the ability tant determinant of SH, is dangerous to the skeleton, of 19-Nor to reverse SH and correct the alterations in particularly the cortical bone [20] . It is also well estabbone histomorphometry. Clearly, after 2 months of urelished that 1-␣-hydroxyvitamin-D 3 has a beneficial effect mia, treatment with the vitamin D analog ameliorated on the histomorphometric changes seen in the bone of the increases in serum creatinine, phosphorus, and PTH CRF patients [21, 22] . Moreover, early treatment with levels. Importantly, 19-Nor did not increase ionized calvitamin D during the development of renal failure can cium significantly above the levels seen in normal rats prevent not only the biochemical changes but also the fed the same high phosphorus diet. However, a minor histologic bone damage induced by SH in uremic patients increase in ionized calcium may also participate in the [23, 24] . Clearly, improvements in PTH suppression and correction of secondary hyperparathyroidism between bone histology were observed in adults and children with the uremic groups.
renal failure who were treated with alfacalcidol [25, 26] . The control of secondary hyperparathyroidism is an Recent studies showed the efficacy of the combined therimportant goal in patients with CRF [19] . 19-Nor is curapy with 1,25-dihydroxyvitamin D 3 and 24,25-dihydroxyrently being used in the treatment of secondary hypervitamin D 3 on biochemical and histologic features of parathyroidism because it suppresses serum PTH levels without producing significant either hypercalcemia or renal osteodystrophy in rats with CRF [27]. Moreover, Normal (N) and uremic (U) rats underwent one of the following experimental protocols: normal control ϩ high phosphorus diet ϩ vehicle for 4 months (left panels), uremic control ϩ high phosphorus diet ϩ vehicle for 4 months (middle panels), and uremic ϩ HP diet ϩ vehicle for the first 2 months of study and during the last 2 months of study ϩ 200 ng three times a week 19-Nor-1,25-(OH) 2 D 2 (right panels). In uremic untreated rats, more cancellous bone, double labels (arrow heads), osteoid and erosion (arrows) were seen (A). The structure of the cortex was distorted, with elevated intracortical porosity (B). In contrast, in 19-Nor-treated animals there was less osteoid, double labeling, intracortical porosity, and bone erosion. 20 mm, Villanueva-stained sections. Abbreviations are: T, trabeculae; M, marrow; O, osteoid; C, cortex; P, porosity. Magnification ϫ160. Normal (N) and uremic (U) rats underwent one of the following experimental protocols for 2 months: normal control ϩ high phosphorus diet ϩ vehicle (left panels), uremic control ϩ high phosphorus diet ϩ vehicle (middle panels), and uremic ϩ high phosphorus diet ϩ 200 ng three times a week 19-Nor-1,25-(OH) 2 D 2 (right panels). Uremic animals had massive osteoid formation, wide interlabel width (arrow heads), bone erosion (arrows) in the proximal tibial metaphysis (A) and had large porosity in the cortex (B). 19-Nor-treated rats had more cancellous bone compared to normal rats, consisting of lamellar bone structure. Moreover, less osteoid, double labeling, intracortical porosity, and bone erosion was seen. 20 m, Villanueva-stained sections. Abbreviations are: T, trabeculae; M, marrow; O, osteoid; C, cortex; P, porosity. Magnification ϫ160.
the effect of the combined administration of 24,25-dihy-CONCLUSION droxyvitamin D 3 and 1-␣-hydroxyvitamin-D 3 was studied 19-Nor was shown to improve mineralization and prein patients with chronic renal insufficiency [28] . Finally, vent the formation of abnormal woven bone. Most imanother vitamin D analog, 22-oxacalcitriol, has been portant, this vitamin D analog suppressed serum PTH shown to significantly decrease serum PTH levels and levels without inducing low bone turnover [36] . These studies in rats with CRF demonstrate that 19-reverse abnormal bone resorption without induction of Nor prevents secondary hyperparathyroidism and ameadynamic bone disease in dogs with renal failure [29] .
liorates the histomorphometric changes induced by ureBecause no long-term studies have evaluated the effimia and high dietary phosphorus. In addition, 19-Nor cacy of 19-Nor in preventing and treating bone disease suppresses serum PTH and improves bone histology in in renal failure, we studied the effects of this compound uremic rats with established severe secondary hyperparaon reducing the bone structure modifications that are thyroidism. Because of its ability to suppress PTH and induced by CRF and further enhanced by high dietary treat renal osteodystrophy in our experimental model phosphorus in uremic rats.
of renal failure, 19-Nor could be considered a tool for To assess the role of 19-Nor on bone in vivo, we pertherapeutic intervention in secondary hyperparathyroidformed bone histomorphometry on rat tibiae from each ism in CRF. These results in uremic rats should be interexperimental condition. Two months of uremia induced preted with caution and cannot be extrapolated to pasignificant histomorphometric changes of both the PTM tients with CRF. Further studies are critical to evaluate and the cross sections of the tibiofibular junctions of the the role of 19-Nor in humans. tibial shafts. The increase in total bone mass was due mainly to an increase in woven bone. In addition, abnor-ACKNOWLEDGMENTS mal bone mineralization was the most obvious change
